SG11201704106VA - Envenomation therapies and related pharmaceutical compositions, systems and kits - Google Patents

Envenomation therapies and related pharmaceutical compositions, systems and kits

Info

Publication number
SG11201704106VA
SG11201704106VA SG11201704106VA SG11201704106VA SG11201704106VA SG 11201704106V A SG11201704106V A SG 11201704106VA SG 11201704106V A SG11201704106V A SG 11201704106VA SG 11201704106V A SG11201704106V A SG 11201704106VA SG 11201704106V A SG11201704106V A SG 11201704106VA
Authority
SG
Singapore
Prior art keywords
envenomation
therapies
kits
systems
pharmaceutical compositions
Prior art date
Application number
SG11201704106VA
Inventor
Matthew R Lewin
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of SG11201704106VA publication Critical patent/SG11201704106VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
SG11201704106VA 2014-11-21 2015-11-20 Envenomation therapies and related pharmaceutical compositions, systems and kits SG11201704106VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462082895P 2014-11-21 2014-11-21
US201562131441P 2015-03-11 2015-03-11
US201562243374P 2015-10-19 2015-10-19
PCT/US2015/061834 WO2016081826A2 (en) 2014-11-21 2015-11-20 Envenomation therapies and related pharmaceutical compositions, systems and kits

Publications (1)

Publication Number Publication Date
SG11201704106VA true SG11201704106VA (en) 2017-06-29

Family

ID=56014685

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704106VA SG11201704106VA (en) 2014-11-21 2015-11-20 Envenomation therapies and related pharmaceutical compositions, systems and kits

Country Status (18)

Country Link
US (2) US11000506B2 (en)
EP (1) EP3220902A4 (en)
JP (1) JP6883515B2 (en)
KR (1) KR20170086089A (en)
CN (1) CN107249578B (en)
AU (1) AU2015349774B2 (en)
BR (1) BR112017010495B1 (en)
CA (1) CA2968383C (en)
CR (1) CR20170259A (en)
EA (1) EA037262B1 (en)
IL (1) IL252418B (en)
MA (1) MA40998A (en)
MX (1) MX2017006551A (en)
MY (1) MY187053A (en)
PH (1) PH12017500927A1 (en)
SG (1) SG11201704106VA (en)
TW (1) TWI745280B (en)
WO (1) WO2016081826A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017152114A1 (en) * 2016-03-04 2017-09-08 Jeffrey Alan Klein Tumescent contravenom drug delivery
WO2017190141A1 (en) * 2016-04-29 2017-11-02 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
US20200009071A1 (en) * 2016-12-16 2020-01-09 The Regents Of The University Of California Neutralizing venomous biomacromolecules
CN110662548A (en) * 2017-02-17 2020-01-07 卡姆瑞斯国际公司 Universal antitoxic liquid
CN108703975A (en) * 2018-08-30 2018-10-26 黄汝怡 A kind of liniment treated poisonous insect and bitten
CN109260196A (en) * 2018-11-08 2019-01-25 中国科学院海洋研究所 Application of the Batimastat as preparation jellyfish dermatitis drug
CN115379836A (en) * 2019-10-15 2022-11-22 奥菲瑞克斯公司 Early management and prevention of sepsis and sepsis-like syndrome
CN112494498A (en) * 2020-12-11 2021-03-16 中国人民解放军海军军医大学 Application of tetracycline in preparation of medicine for preventing or relieving jellyfish sting
WO2022216953A1 (en) * 2021-04-08 2022-10-13 Believe In A Cure, Inc. Compounds for use in increasing foxg1 expression
US20230054792A1 (en) * 2021-05-14 2023-02-23 Liverpool School Of Tropical Medicine Methods and compositions for the treatment of snake bite
CN113817738B (en) * 2021-10-20 2023-06-16 湖南科技学院 Ginkgo long-chain non-coding RNA and application thereof in ginkgolide biosynthesis
WO2023086343A1 (en) * 2021-11-09 2023-05-19 Ophirex, Inc. Compositions and dosage forms for topical and transdermal delivery of actives and methods of use
KR20230131139A (en) 2022-03-04 2023-09-12 한국원자력의학원 Pharmaceutical composition for preventing or treating radiation-induced skin diseases comprising Darapladib or pharmaceutically acceptable salts thereof as an active ingredient

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196193A (en) 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
DK0675110T3 (en) * 1994-04-01 2002-10-07 Lilly Co Eli 1H-indole-3-glyoxylamide sPLA2 inhibitors
AUPP076797A0 (en) 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
DK1613297T3 (en) 2003-04-14 2007-09-24 Lohmann Therapie Syst Lts Therapeutic patch with polysiloxane matrix containing capsaicin
US20070093518A1 (en) 2003-09-19 2007-04-26 Wetherell Janet R Pharmaceutical compositions for the treatment of organophosphate poisoning
EP1684753A2 (en) 2003-10-28 2006-08-02 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof
WO2006088798A2 (en) 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
CA2625436C (en) 2005-10-12 2016-01-05 Annarita Del Gatto Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications
WO2008060362A2 (en) 2006-09-27 2008-05-22 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2009047762A1 (en) * 2007-10-09 2009-04-16 Yeda Research And Development Co. Ltd Compositions and peptides for treatment of envenomation by pla2 containing venoms like bungarus multicinct venom
CN110522905A (en) 2008-01-21 2019-12-03 德莫迪斯公司 Purposes of the serpin in treatment skin disease
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
WO2011049979A2 (en) 2009-10-19 2011-04-28 Amira Pharmaceuticals, Inc. Injectable formulations for intra- articular or peri-articular administration
US20130253060A1 (en) * 2011-09-21 2013-09-26 Harihara M. Mehendale Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS)
WO2013088112A2 (en) 2011-12-16 2013-06-20 Indosys Limited Medicament unit dose cartridge and delivery device
MX2015003035A (en) * 2012-09-10 2015-09-21 Ophirex Inc Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade.
US20140087003A1 (en) 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings

Also Published As

Publication number Publication date
US20210260029A1 (en) 2021-08-26
EP3220902A2 (en) 2017-09-27
IL252418A0 (en) 2017-07-31
US11000506B2 (en) 2021-05-11
BR112017010495A2 (en) 2018-04-03
CN107249578B (en) 2021-01-26
JP6883515B2 (en) 2021-06-09
EP3220902A4 (en) 2018-11-07
WO2016081826A3 (en) 2016-07-14
BR112017010495B1 (en) 2023-12-05
TWI745280B (en) 2021-11-11
CA2968383C (en) 2024-03-12
CA2968383A1 (en) 2016-05-26
KR20170086089A (en) 2017-07-25
JP2017536372A (en) 2017-12-07
EA201791122A1 (en) 2018-04-30
CR20170259A (en) 2017-10-02
MX2017006551A (en) 2018-01-15
MY187053A (en) 2021-08-27
EA037262B1 (en) 2021-03-01
US20170354642A1 (en) 2017-12-14
PH12017500927A1 (en) 2017-11-20
WO2016081826A2 (en) 2016-05-26
AU2015349774B2 (en) 2020-07-02
IL252418B (en) 2021-01-31
CN107249578A (en) 2017-10-13
AU2015349774A1 (en) 2017-06-01
MA40998A (en) 2017-09-26
TW201632204A (en) 2016-09-16

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical compositions and uses thereof
IL252418A0 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
EP3302442A4 (en) Dosage forms and use thereof
EP3328377A4 (en) Compositions and methods for immuno-oncology therapies
EP3129028A4 (en) Pharmaceutical compositions
EP3334706A4 (en) Pillararenes and uses thereof
HK1252026A1 (en) Pharmaceutical combination and uses thereof
EP3160491A4 (en) Pharmaceutical compositions
EP3114315A4 (en) Geosteering systems and methods thereof
EP3231793A4 (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof
EP3253208A4 (en) Combination therapies
EP3141243A4 (en) Pharmaceutical composition
ZA201703398B (en) Pharmaceutical composition and methods
EP3328368A4 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
EP3166623A4 (en) Multi-drug delivery system and uses thereof
EP3281641A4 (en) Medicine
EP3264891A4 (en) Etv2 and uses thereof
EP3190116A4 (en) Pyrazolothiazole compound and medicine
EP3145922A4 (en) Dipicolylamine derivatives and their pharmaceutical uses
IL250844A0 (en) Therapeutic nanoparticles and related compositions, methods and systems
EP3302483A4 (en) Pharmaceutical compositions and use thereof
EP3191093A4 (en) Pharmaceutical compositions
EP3395344A4 (en) Medicine
EP3170512A4 (en) Pharmaceutical composition
EP3204003A4 (en) Selenosugars and therapeutic uses thereof